Swedish Orphan Biovitrum AB · OMXSTO:SOBI
Swedish Orphan Biovitrum AB — Sobi — Investor Presentation (May 2024)
35 slides from Swedish Orphan Biovitrum AB's investor presentation, May 2024
Slide 1: This is Sobi
This is SobiD Investor Presentation May 2024
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains certain forward-looking statements with respect to certain of the Company’s current expectations and projections about future events. These statements, which sometimes use words such as “intend,” “proposed,” “plan,” “expect,” and words of similar
Slide 3: Table of contents
Table of contents Slide Sobi Key facts and business model 4 Latest results - Q4 and Full year 2023 and business area update 12 Sustainability at Sobi 26 Pipeline and upcoming news flow 30 IR contacts 33 Notes 34
Slide 4: Sobi's mission is to transform the lives of people with rare and debilitating diseases
Sobi’s mission is to transform the lives of people with rare and debilitating diseases Sobi Strategy Growing Portfolio Strategic Portfolio 1,800 employees focused on rare diseases Listed on Nasdaq Lead in Haematology Operating in 30 countries and serving ̴70 markets Stockholm: SOBI 5 medicines in la
Slide 5: Rare diseases are an attractive market and expected to grow faster than general pharma
Rare diseases are an attractive market and expected to grow faster than general pharma • ~7,000 rare disease have been identified with only an Sobi well positioned within rare diseases estimated 130 with marketed treatments • High medical unmet need and treatments offering significant Current Sobi A
Slide 6: Business model - source, develop and commercialise in the rare disease space
Business model - source, develop and commercialise in the rare disease space Acquisitions Source Licensing 7 medicines in 9 projects in development Develop (phase 2 through registration) Europe +6% Commercialise 2023: Revenue: SEK 22,123 M North America + 6% (+12% at CER) International +7% (+54% ex
Slide 7: Strong record of successful achievements in delivering medicines to rare disease patients
Strong record of successful achievements in delivering medicines to rare disease patients around the world Selected examples from the Sobi portfolio Source Novimmune Dova Apellis CTI Pharma ITP - FDA approval 2018 PNH - EU approval 2021 MF – FDA approval 2022 pHLH - FDA approval 2018 EU approval 202
Slide 8: Growth driven by core business area and all regions
Growth driven by core business area and all regions Sales (SEK B) Sales (SEK B) Specialty Care Immunology Haematology Europe North America Royalty Rest of World 22.1 22.1 18.8 18.8 15.3 15.5 15.3 15.5 14.2 14.2 9.1 9.1 6.5 6.5 2017 2018 2019 2020 2021 2022 2023 2017 2018 2019 2020 2021 2022 2023 8
Slide 9: Strategic portfolio set to be the main contributor to our revenue
Strategic portfolio set to be the main contributor to our revenue Strong fundamentals for future growth • Strategic Portfolio with ongoing launches and international diversification Strategic portfolio including Aspaveli/Empaveli, Doptelet, Gamifant, Vonjo, Zynlonta, Potential new medicines* Beyfort
Slide 10: Strategic portfolio and execution of our strategy set to deliver strong growth outlook
Strategic portfolio and execution of our strategy set to deliver strong growth outlook C3G / Sobi Strategy IC-MPGN sHLH / Lead in Haematology MAS SEL-212 Capture the value of the pipeline Efanesoctocog New Indications* alfa Grow Immunology New medicines* and Specialty Care Geographical expansion Go
Slide 11: Management Team
Management Team 11 sobi.com/executive committee
Slide 12: Latest results - Q1 2024 and business area update
Latest results - Q1 2024 and business area update
Slide 13: Strategic portfolio delivering top-line growth in all regions
Strategic portfolio delivering top-line growth in all regions Sobi strategy High double-digit performance at CER Revenue Q1 - SEK 6,256 M, +20% Lead in Haematology EBITA margin adjusted 37% Strategic portfolio1 accounting for 35% of sales in Q1 (15% Q1 2023) Capture the value • Vonjo® (SEK 320 M) •
Slide 14: Business growth at CER of 20% in Q1
Business growth at CER of 20% in Q1 Growth driven by launch medicines and geographical expansion Revenue by segment Revenue by region Q1 2024 change ratio Q1 2024 change ratio SEK M % % SEK M % % Haematology 4,075 +46 65 Europe 2,487 +15 40 – Haemophilia 2,746 +23 44 North America 2,244 -3 36 Immuno
Slide 15: Strategic portfolio accounting for 35% of revenue in Q1
Strategic portfolio accounting for 35% of revenue in Q1 Q1 Q1 SEK M Change at CER FY 2023 2024 2023 Aspaveli/Empaveli 240 95 155% 594 Doptelet (excluding China) 756 475 59% 2,420 Gamifant 438 219 100% 1,645 Vonjo 320 - n/a 706 Zynlonta 13 3 >200% 33 Altuviiio royalty 108 1 6% 145 Beyfortus royalty 3
Slide 16: Strategic portfolio set to be the main contributor to our revenue
Strategic portfolio set to be the main contributor to our revenue Portfolio segments and Revenue, MSEK contribution to growth • In Q1 revenue from strategic % change CER portfolio more than doubled in the 6,256 quarter to SEK 2,193 M Strategic portfolio: Aspaveli/Empaveli, • Royalties of Beyfortus a
Slide 17: Growth continues through pipeline and geographical expansion
Growth continues through pipeline and geographical expansion FDA fast track designation received SEL-212 Pipeline (CRG) Aspaveli (C3G/IC-MPGN) Gamifant Doptelet (sHLH) Efanesoctocog alfa Strategic Hemophilia A portfolio Vonjo Beyfortus Aspaveli (MF & tbd) (RSV royalties) (PNH) Zynlonta Doptelet (2L
Slide 18: Haematology: Doptelet continues to show strong momentum
Haematology: Doptelet continues to show strong momentum (growth of 59% at CER in Q1) Doptelet +59% in Q1 • US: Increased uptake driven by higher market share and duration of treatment • Europe and international ongoing growth driven by launches and increased market share • Sales growth 59% at CER fo
Slide 19: Haematology: Aspaveli/Empaveli launch progressing
Haematology: Aspaveli/Empaveli launch progressing Phase 3 data (VALIANT study) in Nephrology expected in 2H 2024 Solid Aspaveli/Empaveli launch trajectory PNH • Launched in more than 27 countries across EU, International and Canada • Q1 sales SEK 240 M Nephrology • Phase 2 NOBLE study in patients wi
Slide 20: Haematology: Vonjo launch elements in place for growth in 2024
Haematology: Vonjo launch elements in place for growth in 2024 Vonjo SEK 320 M • Sales flat quarter on quarter: insufficient amount of new patient starts in 2023 continue to negatively affect sales in Q1 2024 • Strong indicators of growth inflection point • Additional commercial and medical teams in
Slide 21: Haematology: Strong demand in the haemophilia franchise
Haematology: Strong demand in the haemophilia franchise with double digit growth in Q1 Elocta Alprolix +14% Q1 +17% Q1 • Growth from International expansion • Favourable phasing • Party offset by continued price pressure in many regions Sales in SEK million at actual exchange rates; change at consta
Slide 22: Immunology: RSV season declining with Beyfortus demand partially compensating for Synagis decline
Immunology: RSV season declining with Beyfortus demand partially compensating for Synagis decline RSV season Revenue, SEK M Synagis • Sales impacted by early RSV season peak, in December, and competition 4 000 from Beyfortus. 3 500 • Revenue Q1 SEK 520 M 3 000 Beyfortus royalties 2 500 • Strong laun
Slide 23: Immunology: Gamifant strategy increasing market share; Kineret demand
Immunology: Gamifant strategy increasing market share Kineret: increased demand in Europe and US Gamifant Kineret SEK 438 M Gamifant SEK 633 M +100% Q1 • Growth driven by: +19% Q1 • Increase in number of treating centers • Increased patients from new and established centers • Better balanced patient
Slide 24: Q1 2024 Revenue and profit & loss
Q1 2024 Revenue and profit & loss Q1 Q1 Full-year Total revenue (SEK M) Amounts in SEK M 2024 2023 Change 2023 Total revenue 6,256 5,239 19% 22,123 Haematology Immunology Specialty Care 1,2 Adjusted Gross profit 4,735 4,172 13% 17,162 6 844 Adjusted Gross margin 1,2 76% 80% 78% 298 6256 1,2 272 EBIT
Slide 25: Outlook 2024
Outlook 2024 Revenue Anticipated to grow by a high single-digit percentage at CER1 Adjusted EBITA margin Anticipated to be in the mid-30s percentage of revenue 1. Constant exchange rates. 25
Slide 26: Sustainability at Sobi
© @sobl Sustainability at Sobi
Slide 27: Sobi's sustainability strategy supports our strategic business priorities
Sobi’s sustainability strategy supports our strategic business priorities Maintain commitment Always act to patients responsibly Sustainability indices Index 2023 score • Access to treatment • An inclusive and diverse MSCI A (top 26%) • Patient centricity & workplace • Safe, healthy and fair Sustain
Slide 28: Maintain commitment to patients
Maintain commitment to patients For more details: Sustainability performance | Sobi Access to treatment Humanitarian aid Patient centricity • ~ 36,000 people treated* with • Four international patient councils to medicines from Sobi. advise on early clinical development. • Sobi’s main medicines acce
Slide 29: Always act responsibly
Always act responsibly For more details: Sustainability performance | Sobi Caring for employees Reduced footprint Responsible sourcing Compliance • Gender composition (%) • A 77% reduction in CO2- intensity between 2016 95% Mean score 64 95% and 2023 (from 0,3 to 0,07 between completed Code of of So
Slide 30: Pipeline and upcoming news flow
Pipeline and upcoming news flow
Slide 31: Significant events ahead in 2024
Significant events ahead in 2024 Anticipated major pipeline news flow Doptelet Efanesoctocog alfa SEL-212 & Gamifant US & EU (paediatric) EU decision US submissions CN, JP (ITP) 2024 H1 2024 H2 Efanesoctocog alfa – Haemophilia A: Gamifant – sHLH / MAS in • Regulatory decision in EU rheumatological d
Slide 32: Current development pipeline
Current development pipeline Major ongoing clinical studies and medicines in registration in a major region or country 7 medicines in 9 projects in the clinic (phase 2 through registration) Haematology Immunology ITP: immune thrombocytopenia. C3G and IC-MPGN: C3 glomerulopathy and immune-complex mem
Slide 33: Sobi IR contacts
Sobi IR contacts Investors page on sobi.com Gerard Tobin Jen Kretzmann Jörgen Winroth Head of Investor Relations Manager of Stakeholder Senior advisor Investor [email protected] Communication and Corporate Relations, North America +41 79 286 28 83 Access [email protected] jennifer.kretzman
Slide 34: Notes on Haemophilia and RSV business
Notes on Haemophilia and RSV business Haemophilia • Sobi and Sanofi collaborate on the development and commercialisation of Alprolix and Elocta/Eloctate. The companies also collaborate on the development and commercialisation of efanesoctocog alfa, or Altuviiio in the US. • Sobi has final developmen
Slide 35: Thank you
Thank you Sobi is a trademark of Swedish Orphan Biovitrum AB (publ). © 2023 Swedish Orphan Biovitrum AB (publ) – All rights reserved Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm • Sweden www.sobi.com